#1 Clinical Trials Search in Europe

Fallopian tube cancer – Trials in Disease

Go back

Clinical Trials for Fallopian Tube Cancer

There are currently 27 ongoing clinical trials investigating new treatments for fallopian tube cancer. These studies are testing various combinations of chemotherapy, targeted therapies, and immunotherapy drugs to improve outcomes for patients. The trials are being conducted across multiple countries in Europe and beyond, offering patients opportunities to access promising new treatment approaches.

Clinical trial locations

Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

This clinical trial is testing treatment approaches for patients with newly diagnosed advanced ovarian cancer, peritoneal cancer, or fallopian tube cancer. All participants initially receive standard chemotherapy with carboplatin and paclitaxel through intravenous infusion. The study then compares two maintenance treatment strategies: taking niraparib alone versus combining niraparib with bevacizumab.

Main inclusion criteria: Participants must be female, at least 18 years old, with confirmed advanced ovarian, peritoneal, or fallopian tube cancer. They must have good physical function (able to carry out normal activities with minimal limitations), adequate organ function shown by blood tests, and normal or well-controlled blood pressure. The first chemotherapy cycle must begin within 8 weeks after surgery.

Main exclusion criteria: Patients who have had prior cancer treatment are excluded. Those with brain metastases, significant heart disease, major surgery within 4 weeks, active bleeding, serious infections, pregnancy or breastfeeding, or allergies to study medications cannot participate. Patients with recent blood clots or inadequate organ function are also excluded.

Main focus: The trial aims to determine whether adding bevacizumab to niraparib maintenance therapy provides better results than using niraparib alone. The study monitors how long patients remain without cancer progression and assesses overall treatment response and side effects.

Investigational drugs: Niraparib is a PARP inhibitor taken orally that blocks DNA repair in cancer cells. Bevacizumab is an angiogenesis inhibitor given intravenously that blocks blood vessel formation feeding tumors. The chemotherapy drugs carboplatin and paclitaxel are also used in the initial treatment phase.

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

This trial provides continued treatment with olaparib for patients who completed a previous study and are still benefiting from this medication. The study includes patients with various cancer types who have BRCA gene mutations, including ovarian, fallopian tube, and peritoneal cancers.

Main inclusion criteria: Patients must have signed informed consent and must currently be benefiting from treatment in a previous AstraZeneca study with olaparib. They must have been part of a prior cancer study where they received olaparib treatment.

Main exclusion criteria: The trial excludes patients without specific cancer types, including those without epithelial ovarian cancer, metastatic breast cancer, platinum-sensitive relapsed ovarian cancer, gBRCA mutated metastatic pancreatic cancer, prostate cancer, or endometrial cancer. Patients outside the specified age range or not meeting vulnerability criteria are also excluded.

Main focus: The study’s primary objective is to provide continuous olaparib treatment to patients who are still benefiting from it, while monitoring safety and tolerability. Serious adverse events are tracked until 30 days after the last dose.

Investigational drugs: Olaparib is a PARP inhibitor administered orally in tablet or capsule form. It works by blocking the PARP enzyme that helps repair DNA damage in cells, preventing cancer cells from repairing themselves and leading to their death.

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This trial evaluates maintenance treatment for patients with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not progressed after platinum-based chemotherapy. The study compares the combination of mirvetuximab soravtansine with bevacizumab against bevacizumab alone.

Main inclusion criteria: Patients must be at least 18 years old and have received or be receiving platinum-based therapy with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin. They must have shown complete response, partial response, or stable disease after completing therapy and be randomized within 8 weeks of the last platinum dose. Patients must have adequate blood, liver, and kidney function and a performance status of 0 or 1.

Main exclusion criteria: The study excludes patients who do not have platinum-sensitive cancers or those without epithelial ovarian, fallopian tube, or primary peritoneal cancers. Only female patients within the specified age range can participate.

Main focus: The trial aims to compare the effectiveness of combining mirvetuximab soravtansine with bevacizumab versus bevacizumab alone in maintaining patient health and preventing disease progression. The study monitors progression-free survival as the primary measure.

Investigational drugs: Mirvetuximab soravtansine is an antibody-drug conjugate that targets cancer cells with high folate receptor-alpha levels, delivering a toxic agent directly to these cells. Bevacizumab is an angiogenesis inhibitor that blocks blood vessel growth to tumors.

Study of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer

This clinical trial investigates whether adding pembrolizumab to chemotherapy can improve outcomes for patients with low-grade serous ovarian cancer, including fallopian tube and peritoneal cancer. The study compares the combination treatment to chemotherapy alone.

Main inclusion criteria: Patients must be female, at least 18 years old, with confirmed low-grade serous ovarian, fallopian tube, or primary peritoneal cancer. They must have received at least one prior platinum-based therapy and have platinum-sensitive disease (progression more than 6 months after last platinum dose). Patients must have adequate organ and bone marrow function, an ECOG performance status of 0 or 1, and be able to take oral medications.

Main exclusion criteria: The trial excludes patients without recurrent platinum-sensitive low-grade serous ovarian cancer. Only female participants within the specified age range can participate, and those considered part of vulnerable populations are excluded.

Main focus: The study evaluates whether pembrolizumab combined with chemotherapy is more effective than chemotherapy alone in improving progression-free survival. The trial measures the 12-month progression-free survival rate as the primary endpoint.

Investigational drugs: Pembrolizumab is an immune checkpoint inhibitor that blocks the PD-1 pathway, allowing the immune system to recognize and attack cancer cells. It is given by intravenous infusion and is being tested in combination with standard chemotherapy.

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This trial tests raludotatug deruxtecan, a new antibody-drug conjugate, for treating platinum-resistant high-grade cancer. The study compares this treatment to standard chemotherapy options chosen by doctors.

Main inclusion criteria: Patients must provide informed consent and have an ECOG performance status of 0 or 1. They must have confirmed high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer with at least one measurable lesion. Patients should have received 1-3 previous treatments and have platinum-resistant disease. Prior PARP inhibitor treatment is required if BRCA1/2 mutation is present.

Main exclusion criteria: Patients with cancer types other than those specified in the study cannot participate. Only female patients are eligible.

Main focus: The trial evaluates whether raludotatug deruxtecan works better than standard chemotherapy options in treating platinum-resistant cancer. The study measures response rates and progression-free survival.

Investigational drugs: Raludotatug deruxtecan is an antibody-drug conjugate that targets the CDH6 protein on cancer cells, delivering a cytotoxic agent directly to tumors. Standard chemotherapy options include paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and topotecan.

Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

This trial tests a combination of relacorilant with nab-paclitaxel and bevacizumab for treating advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. All three medications are administered to evaluate their combined effectiveness.

Main inclusion criteria: Patients must have confirmed high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer with platinum-resistant disease. They must have received 1-4 previous treatments (up to 5 in some cases) and have at least one measurable lesion. Patients must have adequate organ function, an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months.

Main exclusion criteria: Patients without advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer cannot participate. The study excludes patients who have not undergone optimal debulking surgery or are not newly diagnosed at FIGO Stage III or IV. Only female patients are eligible.

Main focus: The trial aims to determine whether the combination of relacorilant, nab-paclitaxel, and bevacizumab can improve treatment outcomes. The study evaluates progression-free survival, overall response rate, and clinical benefit rate at 24 weeks.

Investigational drugs: Relacorilant is a glucocorticoid receptor antagonist that blocks cortisol effects. Nab-paclitaxel is a taxane chemotherapy agent that stops cell division. Bevacizumab is an angiogenesis inhibitor that blocks blood vessel formation to tumors.

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

This trial compares the combination of niraparib and dostarlimab against chemotherapy for patients with recurrent cancer who cannot receive platinum-based treatment. The study evaluates whether the combination immunotherapy and targeted therapy provides better outcomes.

Main inclusion criteria: Patients must have recurrent cancer that is platinum-resistant or platinum-intolerant, with an ECOG performance status of 0 or 1. They must have measurable disease or be evaluable by RECIST 1.1 criteria, be at least 18 years old, and have adequate organ function. Patients must provide tumor tissue samples and agree to use effective birth control.

Main exclusion criteria: Only female patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer are eligible. Those considered part of vulnerable populations are excluded.

Main focus: The trial evaluates overall survival as the primary outcome, comparing the niraparib-dostarlimab combination to physician’s choice of chemotherapy. The study also measures progression-free survival and response rates.

Investigational drugs: Niraparib is a PARP inhibitor that blocks DNA repair in cancer cells. Dostarlimab is an immune checkpoint inhibitor that blocks the PD-1 receptor, enhancing the immune system’s ability to attack cancer cells.

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

This trial studies whether patients can receive shorter initial chemotherapy (3 cycles instead of 6) before starting niraparib maintenance therapy. The study includes patients with advanced high-grade ovarian cancer who have no remaining tumor after surgery.

Main inclusion criteria: Patients must be female, postmenopausal or non-childbearing, at least 18 years old, and able to take oral medications. They must have advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer (excluding mucinous type) with no visible tumor remaining after surgery. Patients must have adequate organ and bone marrow function and an ECOG performance status of 0 or 1.

Main exclusion criteria: Patients with other cancer types, remaining tumor mass after surgery, or those who have not undergone tumor removal surgery cannot participate. Only female patients are eligible.

Main focus: The study determines whether 3 cycles of chemotherapy followed by niraparib maintenance therapy is as effective as the standard 6 cycles. The trial measures recurrence-free survival as the primary outcome.

Investigational drugs: Niraparib is a PARP inhibitor administered orally that blocks DNA repair enzymes, preventing cancer cells from repairing themselves. It is used as maintenance therapy after initial chemotherapy with carboplatin and paclitaxel.

Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

This non-randomized, open-label trial studies the combination of olaparib and bevacizumab as maintenance therapy after first-line treatment. The study evaluates HRD status using different testing methods.

Main inclusion criteria: Patients must be female, at least 18 years old, with newly diagnosed advanced high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer. They must have an ECOG performance status of 0-1, life expectancy of at least 16 weeks, and adequate organ and bone marrow function. Patients must have completed at least 6 cycles of platinum-taxane chemotherapy and at least 3 cycles of bevacizumab with no disease progression.

Main exclusion criteria: Patients with cancer types or stages other than those specified, or those outside the required age range cannot participate. Only female patients are eligible.

Main focus: The trial aims to determine how well HRD status can be identified using different tests and how this status affects treatment outcomes. The study monitors progression-free survival and overall survival.

Investigational drugs: Olaparib is a PARP inhibitor that blocks DNA repair in cancer cells. Bevacizumab is an angiogenesis inhibitor that blocks blood vessel formation to tumors, reducing their blood supply.

Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

This trial tests whether adding hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery improves outcomes for patients with ovarian cancer. The study compares surgery with HIPEC to surgery alone.

Main inclusion criteria: Patients must be female, aged 18-76 years, willing to follow the study plan, and covered by social security. During surgery, they must have minimal or no visible remaining cancer, blood loss less than 2.5 liters, and no more than two digestive system removals. They must have confirmed epithelial ovarian, fallopian tube, or peritoneal cancer at stage III and adequate organ function.

Main exclusion criteria: Only female patients with the specified cancer types at stage III B-C-IV are eligible. Those not meeting age requirements or considered part of vulnerable populations are excluded.

Main focus: The study evaluates whether HIPEC treatment during surgery leads to better disease-free survival compared to surgery without HIPEC. The trial monitors time without cancer recurrence as the primary measure.

Investigational drugs: HIPEC involves delivering heated cisplatin chemotherapy directly into the abdominal cavity during surgery, enhanced by sodium thiosulfate to reduce side effects. The heat helps improve chemotherapy effectiveness.

Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This trial tests azenosertib (ZN-c3), a new oral medication, for treating high-grade serous cancer. The study is conducted in two phases to evaluate safety, tolerability, and effectiveness.

Main inclusion criteria: Patients must be at least 18 years old with confirmed recurrent high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. They must have platinum-resistant disease with 1-4 previous treatments (up to 5 in some cases), at least one measurable lesion, and an ECOG performance status of 0 or 1. Adequate organ function is required.

Main exclusion criteria: Patients with cancer types other than high-grade serous ovarian, fallopian tube, or primary peritoneal cancer cannot participate. Those outside the specified age range or considered part of vulnerable populations are excluded.

Main focus: The study first determines the safe dose of ZN-c3, then evaluates its effectiveness in reducing tumors. The trial measures objective response rate, response duration, progression-free survival, and overall survival.

Investigational drugs: ZN-c3 is an investigational oral medication that inhibits specific enzymes involved in cancer cell growth and survival, potentially slowing or stopping disease progression.

Summary

The 27 ongoing clinical trials for fallopian tube cancer span multiple European countries, with notable concentrations in Germany, Italy, Belgium, France, and Spain. Several countries including Poland, the Czech Republic, and Hungary are also actively participating in multiple studies. This geographic distribution provides patients across Europe with access to cutting-edge treatments.

The trials focus on various treatment approaches, including PARP inhibitors (niraparib, olaparib, rucaparib), immunotherapy drugs (pembrolizumab, dostarlimab, durvalumab, nivolumab, cemiplimab), antibody-drug conjugates (mirvetuximab soravtansine, farletuzumab ecteribulin, raludotatug deruxtecan), and targeted therapies combined with chemotherapy. Many studies test combinations of these agents, particularly pairing PARP inhibitors or immunotherapy with bevacizumab or chemotherapy.

A significant number of trials target platinum-resistant disease, reflecting the clinical challenge of treating cancers that no longer respond to standard platinum-based chemotherapy. Other studies focus on maintenance therapy following initial treatment, aiming to extend the time patients remain without disease progression. Several trials specifically require tumors to express certain biomarkers, such as folate receptor-alpha or BRCA mutations, representing a move toward more personalized treatment approaches.

The trials employ various study designs, including randomized comparisons of new treatments against standard chemotherapy, dose-escalation studies to determine optimal dosing, and studies evaluating different treatment sequences or durations. Most trials are open to patients who have received limited prior treatments, typically 1-3 previous lines of therapy, though some continuation studies allow patients who are benefiting from treatment to continue receiving it.

Ongoing Clinical Trials on Fallopian tube cancer

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy The Netherlands Spain

  • Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Ireland +2

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Poland Spain

  • Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Poland Spain

  • Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Germany Italy

  • Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +6

  • Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy

  • Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Germany Italy Spain

More information about
Fallopian tube cancer:

Connected medications: